Effect of Intensive Versus Standard Blood Glucose Control in Patients With Type 2 Diabetes Mellitus in Different Regions of the World: Systematic Review and Meta‐analysis of Randomized Controlled Trials

Abstract

Background Regional variation in type 2 diabetes mellitus care may affect outcomes in patients treated with intensive versus standard blood glucose control. We sought to evaluate these differences between North America and the rest of the world. Methods and Results Databases were searched from their inception through December 2013. Randomized controlled trials comparing the effects of intensive therapy with standard therapy for macro‐ and microvascular complications in adults with type 2 diabetes mellitus were selected. We calculated summary odds ratios ( OR s) and 95% CI s with the random‐effects model. The analysis included 34 967 patients from 17 randomized controlled trials (7 in North America and 10 in the rest of the world). There were no significant differences between intensive and standard therapy groups for all‐cause mortality ( OR 1.03, 95% CI 0.93 to 1.13) and cardiovascular mortality ( OR 1.09, 95% CI 0.90 to 1.32). For trials conducted in North America, intensive therapy compared with standard glycemic control resulted in significantly higher all‐cause mortality ( OR 1.21, 95% CI 1.05 to 1.40) and cardiovascular mortality ( OR 1.41, 95% CI 1.05 to 1.90) than trials conducted in the rest of the world (all‐cause mortality OR 0.93, 95% CI 0.85 to 1.03; interaction P=0.006; cardiovascular mortality OR 0.89, 95% CI , 0.79 to 1.00; interaction P=0.007). Analysis of individual macro‐ and microvascular outcomes revealed no significant regional differences; however, the risk of severe hypoglycemia was significantly higher in trials of intensive therapy in North America ( OR 3.52, 95% CI 3.07 to 4.03) compared with the rest of the world ( OR 1.45, 95% CI 0.85 to 2.47; interaction P=0.001). Conclusion Randomization to intensive glycemic control in type 2 diabetes mellitus patients was associated with increases in all‐cause mortality, cardiovascular mortality, and severe hypoglycemia in North America compared with the rest of the world. Further investigation into the pathobiology or patient variability underlying these findings is warranted.